Structurally distinct external solvent-exposed domains drive replication of major human prions

Mohammad Khursheed Siddiqi, Chae Kim, Tracy Haldiman, Miroslava Kacirova, Benlian Wang, Jen Bohon, Mark R. Chance, Janna Kiselar, Jiri G. Safar

1 Department of Pathology, Case Western Reserve University, Cleveland, Ohio, United States of America
2 Department of Nutrition, Case Western Reserve University, Cleveland, Ohio, United States of America
3 Center for Proteomics and Bioinformatics, Case Center for Synchrotron Biosciences, Brookhaven National Laboratory, Upton, New York, United States of America
4 Department of Neurology, Case Western Reserve University, Cleveland, Ohio, United States of America

¤a Current address: Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic
¤b Current address: Advanced Sources and Detectors Project Office, Los Alamos National Laboratory, Los Alamos, New Mexico, United States of America
* jiri.safar@case.edu

Abstract

There is a limited understanding of structural attributes that encode the iatrogenic transmissibility and various phenotypes of prions causing the most common human prion disease, sporadic Creutzfeldt-Jakob disease (sCJD). Here we report the detailed structural differences between major sCJD MM1, MM2, and VV2 prions determined with two complementary synchrotron hydroxyl radical footprinting techniques—mass spectrometry (MS) and conformation dependent immunoassay (CDI) with a panel of Europium-labeled antibodies. Both approaches clearly demonstrate that the phenotypically distant prions differ in a major way with regard to their structural organization, and synchrotron-generated hydroxyl radicals progressively inhibit their seeding potency in a strain and structure-specific manner. Moreover, the seeding rate of sCJD prions is primarily determined by strain-specific structural organization of solvent-exposed external domains of human prion particles that control the seeding activity. Structural characteristics of human prion strains suggest that subtle changes in the organization of surface domains play a critical role as a determinant of human prion infectivity, propagation rate, and targeting of specific brain structures.

Author summary

Sporadic human prion diseases are conceivably the most heterogenous neurodegenerative disorders and a growing body of research indicates that they are caused by distinct strains of prions. By parallel monitoring their replication potency and progressive hydroxyl radical modification of amino acid side chains during synchrotron irradiation, we identified major differences in the structural organization that correlate with distinct inactivation
susceptibility of a given human prion strain. Furthermore, our data demonstrated, for the first time, that seeding activity of different strains of infectious brain-derived human prions is primarily function of distinct solvent-exposed structural domains, and implicate them in the initial binding of cellular isoform of prion protein (PrPC) as a critical step in human prion replication and infectivity.

Introduction

Prions are a distinct class of infectious agents that are composed of self-replicating misfolded protein aggregates and are causing invariably fatal neurodegenerative diseases affecting both humans and animals. The rapidly progressing neurodegeneration is caused by a pathogenic protein, designated PrP\textsuperscript{Sc} [1], a misfolded isoform of the normal cellular prion protein [2–7], PrP\textsuperscript{C}. Humans prion diseases include Gerstmann-Sträussler-Scheinker disease (GSS), fatal insomnia (FI), kuru, variably protease-sensitive prionopathy (VPSPR), and Creutzfeldt-Jakob disease (CJD) [8–11]. The sporadic form of Creutzfeldt-Jakob disease (sCJD) is the most prevalent and accounts for ~90% of cases globally [9–11]. In contrast to stable cloned laboratory and animal prions, human prions are perhaps the most phenotypically diverse; they exist in a broad spectrum of strains causing at least eight diverse clinicopathological disease phenotypes, and may undergo further mutation and evolution by a conformational selection mechanism [12]. Codon 129 (M or V) polymorphism in PRNP gene has a major impact on disease phenotype and progression rate and is used together with 21kDa (type 1) or 19kDa (type 2) mass of protease resistant core of sCJD prions into clinicopathological classification, with sCJD MM1, MM2, and VV2 which are representing ~80% of all cases [9–11].

A number of studies have demonstrated that rodent prions can be generated in vitro from bacterially-expressed recombinant mouse or Syrian hamster PrP [13–17], and these experiments played a fundamentally important role in providing the ultimate proof for the protein-only hypothesis of prion diseases [15, 16, 18–21]. However, our early data using hydrogen/deuterium exchange and mass spectrometry indicated that human prions causing sporadic Creutzfeldt-Jakob disease (sCJD) differ in a major way from both cloned laboratory prions and synthetic prion amyloids, and phenotypically distant MM1 sCJD prions further differ in their structural organization from MM2 sCJD prions [22, 23]. Additionally, by comparing the structural organization of human prions that we recently synthesized in vitro [24] with that of parent sCJD MM1 prions and noninfectious human prion protein amyloid, we have identified critical differences in PrP that are important for the initiation of replication in vivo, i.e. their infectivity. Moreover, these data indicated that, in contrast to previous observations on yeast and some murine prion strains, the replication rate of sCJD prions is primarily determined not by conformational stability, but by their unique structural features that control the growth rate of prion protein aggregates [22]. Although these structural and functional insights implicate the initial interaction between prion seed and PrP\textsuperscript{C} substrate as a critical step in human prion replication and propagation, the structural elements (domains) driving this process, and the role of different codon 129M or 129V polymorphisms are not known. A growing body of evidence indicates that the improved understanding of this mechanism in human CJD prions will have major implications for other age-related neurodegenerative diseases linked to other misfolded proteins, including an ongoing debate about their potential transmissibility [25–27].

In order to gain insight into the impact of the structural organization of major human brain derived sCJD MM1, MM2, and VV2 prion strains on their replication and inactivation, we employed two different synchrotron hydroxyl radical (’OH) footprinting techniques. The
first is a novel epitope interference study, where the affinity of a panel of monoclonal antibodies with linear epitopes in PrP monomers and sCJD prions is progressively altered by modifying key amino acids side chains by hydroxyl radicals produced with increasing doses of synchrotron radiation, and the changes are monitored by quantitative and conformationally dependent immunoassays (CDIs). The differences in kinetics of epitope modification evaluated across both PrP monomer forms and sCJD prions indicate differences in accessibility to solvent due to the differences in conformation. Further, the hydroxyl radical induced modifications are assessed after proteolysis with mass spectrometry (MS) that provide the data on PrP monomers and sCJD MM1, MM2 and VV2 prions at a single residue resolution. Both footprinting techniques indicate that the distribution of critical surface amino acid residues is an important determinant of the structural heterogeneity in human brain derived sCJD MM1, MM2 and VV2 strains and is responsible for differences in replication rate, resistance to inactivation, and pathological targeting of different brain structures observed in sCJD patients.

Materials and methods

Ethics statement

All procedures were strictly implemented under the standard protocols (IRB Number 03-14-28) approved by the Institutional Review Board at Schools of Medicine, Case Western Reserve University, and University Hospitals Case Medical Centre. For all the cases associated with our investigation, written informed consents for research were acquired from patients’ or legal guardians, and the material during research had appropriate ethical approval for use in this project. All patients’ data and samples were coded, anonymized, and operated in accordance with NIH guidelines in order to protect patients’ identities.

Sporadic CJD (sCJD) case demographics

From the collection of samples obtained from 343 patients with an unequivocal neuropathological diagnosis of sporadic CJD MM1, CJD MM2, and CJD VV2, we selected one case that is representative of each neuropathology group (Fig 1) and displayed ≥99% pure Type 1 or Type 2 proteinase K-resistant PrP\textsuperscript{Sc} (rPrP\textsuperscript{Sc}), as detected by both conformation dependent immunoassay (CDI) and Western blots [11, 28–30]. The disease duration in these representative cases, as well as biochemical characteristics of brain PrP\textsuperscript{Sc} associated with them (levels of total PrP\textsuperscript{Sc} and rPrP\textsuperscript{Sc}, size of PrP\textsuperscript{Sc} particles, and conformational stability of PrP\textsuperscript{Sc}) correspond to the respective median values reported previously for each group [29, 30] (Table 1).

Purification of MM1, MM2, and VV2 prions

The purification of PrP\textsuperscript{Sc} from human brains was adopted for human prions [22] from previously described purification of 263K prions from Syrian hamster brains [31–33]. Briefly, CJD brain cortex slices weighing ~24g were disrupted to final 5% (w/v) homogenate in ice-cold PBS (pH 7.4) containing 2% (w/v) Sarkosyl by three 50-s cycles in Omni TH-01 homogenizer equipped with disposable plastic probes (Thermo Fisher Scientific, Waltham, Massachusetts) and clarified for 5min at 500xg in Allegra centrifuge (Beckman Coulter, Brea, California) equipped with S-2415 rotor. The clarified 5% brain homogenate was spun for 30min at 185,000xg at 4˚C in Optima XPN-100 ultracentrifuge equipped with Ti 50.2 rotor (Beckman Coulter, Brea, California), and the pellets were resuspended in PBS, pH 7.4 containing 10% (w/v) NaCl and 1% Sarkosyl. After incubation in Eppendorf Thermomixer (Eppendorf, Hauppauge, NY) for 2 h at 37˚C with 600rpm shaking, the samples were spun for 2hrs at 26,000xg.
Fig 1. Distinct disease duration, schematic representation, and molecular characteristics of sCJD MM1, MM2, and VV2 prions. (a) The age (left panel) and disease duration (right panel) in 343 cases of sporadic CJD MM1, MM2, and VV2 prion disease; (b) Outline of classification of Type 1 and Type 2 human prions based on proteolytic fragmentation of PrP\textsuperscript{Sc} [75, 89]. Major cleavage sites by PK are indicated by arrows; GLP–glycolipid; CHO–complex N-glycosylation chains. The codes above light blue brackets represent monoclonal antibodies used in differentiation of various domains of human prions, and the numbers below these brackets indicate linear epitopes recognized by these antibodies. (c) Distinct glycosylation and Proteinase K fragmentation patterns of purified human MM1, MM2, and VV2 sCJD rPrP\textsuperscript{Sc} (homozygous for methionine [M] or valine [V] in codon 129) used in structural studies. To differentiate Type 1, Type 2 prions, and their C-terminal fragments, Western blots of purified rPrP\textsuperscript{Sc} (fraction 8; F8) of MM1, MM2, and VV2 sCJD rPrP\textsuperscript{Sc} were developed with
and 4°C in F2402H rotor of Beckman Allegra centrifuge. The partially purified samples containing ~10 μg of human PrPSc were resuspended in PBS, pH7.4 containing 2mM CaCl2 and 2% Sarkosyl, sonicated in a sonication bath (3x5s), and incubated for 4hrs at 37°C with 70 μg/ml of Collagenase (Worthington Biochemical Corporation) and shaking at 600rpm in Eppendorf Thermomixer. After adding MgCl2 to a final 5mM concentration, the samples were incubated with 50IU/ml of Benzonase (Novagen/EMP) for additional 1hr at 37°C, followed by 1hr incubation with Proteinase K (Amresco, Solon, OH/ Invitrogen) at 37°C and 1:50 enzyme/total protein ratio (w/w). The Proteinase K was blocked with protease inhibitor (PI) cocktail containing 0.5mM PMSF, and 2 μg/ml of aprotinin and leupeptin, respectively. The pellet obtained after centrifugation (30min, 26,000xg, 4°C) in Allegra centrifuge equipped with F2402H rotor was resuspended in PBS containing 2% Sarkosyl and PI cocktail (1:1000, v/v), and delipidated overnight with four volumes of Methanol/Chloroform (2:1, v/v) at -20°C. Finally, the sample was collected by centrifugation, resuspended in water containing 0.1% Sarkosyl and stored at -80°C for further analysis.

Synchrotron radiolysis

Radiolysis experiments were performed at the 17-BM X-ray footprinting (XFP) beamline of the National Synchrotron Light Source II, at Brookhaven National Laboratory (NY, USA) and the approved biosafety protocols covering the human prion experiments are available upon request. The irradiation time in X-ray beam with 5–16 keV energy, current 300 mA, and no Aluminum shielding was optimized by using Alexa-488 fluorophore assay [34]. The 1 μg aliquots of rPrP(C) (129M and 129V) and sCJD brain-derived rPrPSc (MM1, MM2 and VV2) in closed thin-wall PCR (Axygen) tubes were exposed for 0–70 ms and 0–200 ms, respectively. After irradiation, samples were immediately quenched with methionine amide (20mM, final concentration) to prevent any secondary oxidation by left over radicals [35]; and stored at -80°C until they were studied.

Table 1. Demographics, molecular characteristics, and synchrotron hydroxyl radical inactivation of different strains of sCJD prions. Conformational stability assay (CSA) of prions is expressed in a midpoint concentration of the GdnHCl in the transition from folded to unfolded state [24, 29, 30, 39].

| Parameter                  | Unit   | sCJD MM1 | sCJD MM2 | sCJD VV2 |
|----------------------------|--------|----------|----------|----------|
| Age                        | years  | 57       | 73       | 63       |
| Sex                        | F/M    | F        | F        | M        |
| Disease Duration           | month  | 2        | 46       | 6        |
| Postmortem Interval        | hrs    | 2        | 72       | 24       |
| PRNP codon 129             | M/V    | MM       | MM       | VV       |
| Neuropathology Classification| -      | sCJDMM(MV)1 | sCJDMM2C | sCJDVV2  |
| Mass of Unglycosylated rPrPSc | kDa    | 21       | 19       | 19       |
| CSA GdnHCl1/2              | [M]    | 2.95±0.09| 1.64±0.06| 2.76±0.15|
| Synchrotron Irradiation Time 0ms Log10 SD30/μg | 8.29 | 7.84 | 8.04 |
| 30ms                       | 7.84   | 6.84     | 7.84     |
| 90ms                       | 7.34   | 6.64     | 7.34     |
| 200ms                      | 6.39   | 5.89     | 6.39     |
| Prion Irradiation half-life | ms     | 19.4     | 7.6      | 43.2     |

https://doi.org/10.1371/journal.ppat.1009642.t001
Molecular characteristics and physicochemical properties of purified sCJD prions

The purified rPrPsc was analyzed by SDS PAGE followed by silver staining and western blots, and by conformation-stability assay (CSA). The latter assay was performed as described previously [30, 36] with the following minor modifications. First, we used white LumiTrac 600 High Binding Plates (E&K Scientific, Santa Clara, California) coated with mAb 8H4 (epitope 145–185) [37] in 200 mM NaH2PO4 containing 0.03% (w/v) NaN3, pH 7.5. Second, aliquots of 20 μl from each fraction containing 0.007% (v/v) of Patent Blue V (Sigma) were directly loaded into wells of white strip plates prefilled with 200 μl of Assay Buffer (Perkin Elmer, Waltham, Massachusetts). Finally, the captured PrP was detected by a europium-conjugated [38, 39] anti-PrP mAb 3F4 (epitope 108–112) and the time-resolved fluorescence (TRF) signals were measured by the multi-mode microplate reader PHERAstar Plus (BMG LabTech, Durham, North Carolina). The recHuPrP(90–231,129M) and PrP(23–231,129V) used as a calibrant in the CDI was prepared and purified as described previously [40]. The conformational stability of rPrPsc was determined as described previously [30, 39] and the raw CDI signal was converted into the apparent fractional change and fitted by least square method with a sigmoidal transition model to determine GdnHCl concentration where 50% of PrPsc is unfolded ([Gdn HCl]1/2) [30].

Seeding activity of human prions in second generation real-time quaking-induced conversion (RT-QuIC)

The second generation RT-QuIC for human prions, purification, and refolding of prion protein substrate were performed as previously described [41] with minor modifications. Briefly, 98 μL of fresh RT-QuIC reaction mix (10 mM phosphate buffer pH 7.4; 300 mM NaCl; 0.1 mg/mL recombinant PrP; 10 μM Thioflavin T and 1 mM EDTA) was loaded into the wells of a black 96-well clear bottom plate (Nunc). The wells were then seeded with 2 μL of the serially diluted brain homogenate (BH) control or synchrotron irradiated purified prions for a final volume of 100 μL. All samples contained 0.1% SDS resulting in final concentration of 0.002% final concentration of SDS in the reaction mix. Plates were sealed (Nalgene Nunc International sealer) and incubated in a BMG FLUOstar Omega plate reader (BMG Labtech, Ortenberg, Germany) at 55˚C for the designated period of 60hrs with cycles of 1 min shaking (700rpm double orbital) and 1 min rest through the incubation. ThT fluorescence measurements (450±10nm excitation and 480±10nm emission; bottom read) were taken every 45 minutes. The ThT positive wells were determined as described for prion diagnostic applications [41], with wells concluded to be positive if the ThT fluorescence exceeded the cutoff calculated as a mean ± 4* standard deviations (SD) of all prion-negative wells on a given plate.

Seeding Activity (SD50) calculations

The Spearman-Kärber analysis analogous to calculations of 50% prion lethal dose (LD50) in bioassays [36, 42–45] was used to estimate a seeding dose or dilution at which 50% of the wells became ThT positive (SD50) [46]. Each sample corresponding to the 0, 30, 90, and 200ms of synchrotron irradiation was 5-fold serially diluted and each dilution was tested in four wells in RT QuIC. The 50% seeding end-point was calculated using the following formula: \( x_p = 1 + 1/2d \cdot d \sum p \) (where \( x_p = 1 \) is the highest log dilution giving all positive responses; \( d = \log \) dilution factor; \( p = \) proportion positive at a given dose; \( \sum p = \) the sum of values of \( p \) for \( x_p = 1 \) and all higher dilutions.)
Synchrotron •OH epitope modification monitored with direct Conformation Dependent Immunoassay (CDI)

The direct CDI format for human prions was performed as described previously [23, 24, 29, 30, 36] with the following minor modifications. All antibodies were Europium-labeled according to our previously published protocol [39] resulting in a density of 4.3–6.3 Eu per IgG, and calibrated against recombinant human prion protein and diluted to obtain the same signal (Fig 2A). Synchrotron irradiated monomeric recombinant PrP and brain derived sCJD MM1, MM2, VV2 prions were diluted in 4M GdnHCl to a constant concentration and then heated at 80 °C for 5 min. Denatured samples were further diluted in PBS to a final 0.2M GdnHCl and loaded onto a 96-well high-binding polystyrene plate. Sample loaded plates were incubated overnight at 4 °C and blocked with either casein (Surmodics, Eden Prairie, MN) solution (1x casein, 0.05% Tween 20 and 6% sorbitol) or BSA (0.25% BSA, 0.05% Tween 20 and 6% sorbitol) in PBS. The blocked plates were incubated for two hours with Europium conjugated antibodies: Eu-3F4 [47] (Biolegend, San Diego, CA), epitope aa108-112; Eu-6D11, (Biolegend, San Diego, CA), epitope aa93-109; Eu-8H4 [37], epitope aa145-185, (gift from Dr. Man-Sun Sy, CWRU); Eu-1E5, (Santa Cruz Biotechnology, Dallas, TX), epitope aa145-149; Eu-5B9, (Dia-nova Gmbh, Hamburg, GE), epitope aa157-167; and Eu-MAR1 [48], epitope aa179-214 (CSL Behring BMGH), and detected by monitoring the time-resolved fluorescence signal using multi-mode microplate reader PHERAstar Plus (BMG Lab Tech, Durham, NC).

The modification rate constant for each specific epitope was calculated by fitting the fraction unmodified for this modification site to the equation: $F_u(t) = F_u(0)e^{-kt}$, where $F_u(0)$ and $F_u(t)$ are the fraction of unmodified epitope at time zero and time t, respectively; and k is first order rate constant [49, 50]. The half-life ($t_{1/2}$) for modification of amino acid residues in a given antibody epitope was calculated using equation: $t_{1/2} (sec) = \ln2/k$, where k (sec$^{-1}$) is the rate constant [51, 52].

Mass spectrometry (MS) analysis of •OH footprinting

Before proteolysis, all samples were denatured and reduced by the addition of 96% formic acid (FA) and 4mM tris 2-carboxyethylphosphine (TCEP). The supernatant, dried overnight in a vacuum desiccator filled with solid Na$_2$CO$_3$, was solubilized in 4.5% (v/v) FA and 4mM TCEP, sonicated, mixed with pepsin (Promega) at a pepsin-to-protein ratio (w/w) of 1:5, and incubated for 5hrs at 37 °C with continuous shaking at 350rpm. Pepsin was inactivated by heating the sample at 95 °C for 3 min.

Identification and quantification of oxidative sites were performed by LC-MS analysis using an Orbitrap Eclipse mass spectrometer (Thermo Scientific, CA) interfaced with a Waters nanoAcquity UPLC system (Waters, MA). Proteolytic peptides (~600 ng in 8μl; ~300ng in 4μl) were loaded on a trap column (180 μm × 20 mm packed with C18 Symmetry, 5 μm, 100 Å; Waters, MA) to desalt and concentrate peptides. Peptide mixture was separated on a reverse phase column (75 μm x 250 mm column packed with C18 BEH130, 1.7 μm, 130 Å; Waters, MA) using a linear gradient of 0 to 32% mobile phase B (0.1% formic acid and acetonitrile) vs. mobile phase A (100% water/0.1% formic acid) for 60 minutes at 40 °C at a flow rate of 300 nL/min. Eluted peptides were introduced into the nano-electrospray source at a capillary voltage of 2.0 kV. MS1 spectra were acquired for all eluted peptides in the Orbitrap mass analyzer (R = 120K: AGC target = 400,000; MaxIT = auto; RF Lens = 30%; mass range = 350–1500). MS/MS spectra were collected in the linear ion trap mass analyzer (rate turbo); AGC target 10,000; MaxIT = 35 ms; NCE$_{CDI}$ = 35%). The resulting MS/MS spectra were searched against a database that consists of full prion protein sequence using Mass Matrix software to identify specific sites of modification. In particular, MS/MS spectra were searched for peptides generated by pepsin digestion.
using mass accuracy values of 10 ppm and 0.8 Daltons for MS1 and MS/MS scans respectively, with allowed variable modifications for all known oxidative modifications previously documented for amino acid side chains [53, 54]. In addition, MS/MS spectra for each site of proposed modification were manually validated.

Hydroxylation rate analysis
For the residue level analysis, the integrated peak areas of the unmodified peptide ($A_u$), and each specific modified product ($A_m$) for this peptide derived from selected ion chromatograms, were used to calculate percent modification and fraction unmodified ($F_u$) for specific site of modification using the following equation:

$$\text{Percent modification} = \left[ \frac{A_m}{(A_u + \sum A_m)} \right] \times 100$$

Fraction unmodified, $F_u = 1 - \left[ \frac{A_m}{(A_u + \sum A_m)} \right]$

Where, $\sum A_m$ is the sum of all modified peak area from a particular peptide. The dose-response curve for each specific modification was generated using fraction unmodified for each specific site plotted versus X-ray exposure time. The modification rate constant for each specific modification was calculated by fitting the fraction unmodified for this modification site to the equation: $F_u(t) = F_u(0)e^{-kt}$, where $F_u(0)$ and $F_u(t)$ are the fraction of unmodified residue at time zero and time $t$, respectively; and $k$ is first order rate constant [49, 50]. The half-life ($t_{1/2}$) for modification of amino acid residue was calculated using the equation: $t_{1/2} (\text{sec}) = \ln 2/k$, where $k (\text{sec}^{-1})$ is the rate constant [51, 52]. For comparing the difference in exposure of the amino acid residues between recPrP and PrP\textsuperscript{Sc} we calculated the modification rate ratio (protection factor) by dividing the modification rate of residue in recPrP with the modification rate of same residue in PrP\textsuperscript{Sc} [55, 56].

Statistical analysis
Statistical analysis was performed using SPSS Statistics 27 package (IBM) or KaliedaGraph (Synergy) software, and 3D modelling with PyMOL software. Experimental results were expressed as mean ± SEM, and a post hoc test (Dunnet) was used to calculate the $P$ values. Significance level ($\alpha$) was set to $p<0.05$.

Results
Molecular characteristics of CJD MM1, MM2, and VV2 prions
From the collection of samples obtained from 343 patients with an unequivocal diagnosis of Type 1 (MM1), Type 2 (MM2), and Type 2 (VV2) sCJD, we selected one case that is representative of each neuropathology group (Fig 1) and displayed ≥99% pure Type 1 or Type 2 proteinase K-resistant PrP\textsuperscript{Sc} (rPrP\textsuperscript{Sc}), as detected by Western blots [28–30]. The disease duration in these representative cases, as well as biochemical characteristics of brain PrP\textsuperscript{Sc} associated with them (levels of total PrP\textsuperscript{Sc} and rPrP\textsuperscript{Sc}, conformational stability of PrP\textsuperscript{Sc}) correspond to the values reported previously for each group [12, 22, 29, 30] (Table 1).

Western blot patterns and silver staining of purified protease resistant cores (rPrP\textsuperscript{Sc}) of MM1, MM2, and VV2 in the final fraction 8 (F8) demonstrated expected [22, 57] characteristics, the mass of unglycosylated fragments was ~21 kDa in Type 1 and ~19 kDa in Type 2 rPrP\textsuperscript{Sc}, and Type 2 rPrP\textsuperscript{Sc} was not detectable with mAb 12B2 due to the missing N-terminal epitope (Fig 1B and 1C). The complex band patterns are due to the presence of 2, 1, or no N-linked glycosylation chains, and ~13–15 kDa C-terminal fragments (CTFs) that were more
abundant in Type 2 rPrPSc and detectable in Type 1 after longer exposure (Fig 1C) [22]. The isolated rPrPSc was ~90% pure (Fig 1C) [22]. These patterns were highly reproducible upon purification of rPrPSc from different cortical areas of the same brain [22].

Monitoring epitope modification by synchrotron generated •OHs with direct conformation-dependent immunoassay (dCDI)

Testing the existence of phenotype-specific conformational differences between human brain-derived prion strains in polymorphic fibrillar, oligomeric, and monomeric structures has been difficult due to the lack of adequate experimental approaches suitable for all these major forms. The recently developed ultrafast synchrotron •OH footprinting is suitable for structural studies of all forms [49, 50, 54, 58] and here we expanded this methodology by monitoring the rate of epitope modification with a panel of Europium labeled monoclonal antibodies in direct conformation-dependent immunoassay (dCDI) [23, 24, 26, 29, 30, 39, 59, 60]. In this protocol, the amino acid side chains modification by OH radicals generated by radiolysis of water in a synchrotron beam led to a time-dependent loss of monoclonal antibody affinity, and the rate of residue modification is proportional to extent of solvent exposure in the native prion structure.

We selected and labeled with Europium six monoclonal antibodies with linear epitopes covering major domains of the CJD prion cores. All demonstrated a parallel response to concentration of monomeric recombinant human prion protein (recPrP) in direct CDI and pg/ml sensitivity (Fig 2A). The α-helical monomers of rPrP lost 95–99.9% of antibody affinity after 10ms of irradiation and the antibody signal continued dropping at a slower rate to 50ms where it reached a plateau. The phases are strikingly distinct for all six antibodies, and the least reactive after 10 ms (eg. 5B9, 3F4, 6D11), continue to be more resistant to further interference as a function of modification compared to the other 3 epitopes (8H4, MAR1, and 1E5) (Fig 2B).

In comparison to the α-helical monomer of recPrP, all epitopes of brain-derived sCJD MM1, MM2, and VV2 prions demonstrated several orders of magnitude slower modification rate by •OH radicals, with major differences between sCJD MM1, MM2, and VV2 prions (Fig 2C, 2D, 2E, 2F, 2G and 2H). With the exception of the 145–185 sequence, all domains of sCJD MM1 prions were more protected, followed by MM2 and VV2 prions. The half-life of each epitope during synchrotron irradiation calculated from exponential decay models revealed the distinctly different patterns of MM1, MM2, and VV2 prions (Fig 2I). We observed the highest protection of MM1 prions in two distant epitopes—aa108-112 and aa157-167, opposite trends in VV2 prions, and intermediate protection in all domains of MM2 prions.

Replication potency of synchrotron-irradiated prions

Evidence accumulated with prions and more recently with a growing list of other proteins indicate that the misfolded conformers can be amplified with recombinant substrates in a seeded reaction in vitro—a prerequisite step for misfolding propagation in the brain [22, 24,
At initial $10^{-6}$ dilution of purified prions, we observed lower ThT fluorescence, and in MM2 prions an extended lag phase after 200ms irradiation (Fig 3). Next, we performed systematic endpoint titration of seeding potency of synchrotron irradiated prions using second generation RT QuIC of serially diluted samples \(^{[41]}\) (S1 Table). To estimate a seeding dose or dilution at which 50% of the wells became ThT positive ($\log_{10}$ SD$_{50}$) \(^{[46]}\), we employed the Spearman–Kärber analysis, analogous to calculations of 50% prion lethal dose ($LD_{50}$) in prion bioassays \([36, 42–45]\). The end-point titration data revealed a progressive drop in prion seeding activity and distinctly different seeding inactivation kinetics, with 79-, 89-, and 45-fold less seeding activity of MM1, MM2, and VV2 prions, respectively, after 200ms of irradiation. The major drop in sCJD MM1 prions seeding activity (Fig 3) correlates with rapid modifications of solvent-exposed amino acid side chains in 93–109, 145–185, and 179–
Fig 3. Inactivation rate of human sCJD MM1, MM2, and VV2 sCJD prions by synchrotron •OH. The end-point seeding activity of serially diluted MM1 prions (a) before and (b) after synchrotron irradiation, end-point seeding activity of serially diluted MM2 prions (c) before and (d) after irradiation, and seeding activity of serially diluted VV2 prions (e) before and (f) after synchrotron irradiation. The sCJD prions were irradiated in synchrotron for 0 to 200 ms, serially diluted, and seeding potency of each dilution was monitored by second generation RT-QuIC [41]. The curves in a-f are thioflavin T (ThT) fluorescence averaged at each sample dilution from four wells of 96-well RT QuIC plate as
214 domains, while the rest of the sequence is highly protected (Fig 2), and the MM2 prions show similar trends. The irradiation of VV2 prions demonstrated a delayed and less significant impact on seeding activity (Figs 2 and 3). Cumulatively, the distinct structural organization of each sCJD prion strain appears to determine different inactivation kinetics by •OH radicals, and the rapid kinetics implicate modifications of distinctly solvent-exposed domains.

**Synchrotron •OH footprinting monitored by mass spectrometry**

The dCDI monitoring of the hydroxylation rate of a given antibody epitope in human prion is a new addition to the •OH footprinting techniques and it is a function of (i) solvent accessibility in a native conformation, and (ii) different hydroxylation rates of different amino acids within the epitope sequence [61]. These attributes allow us to compare the hydroxylation rates of the same epitope in different human prions with high sensitivity, even though the hydroxylation kinetics of different epitopes is primarily driven by epitope span, sequence, and sensitivity of particular antibody to the amino acid side chain modifications. As a result, the epitopes differ in hydroxylation kinetics in the same protein and up to 100-fold in the residual signals, as demonstrated with recombinant alpha-helical monomers of PrP (Fig 2B).

Although dCDI monitoring of synchrotron-induced hydroxylation demonstrated high sensitivity and differential power for different prion strains, it measures the cumulative changes originating from the different residues at the domain level dictated by the sequence of antibody epitope and antibody affinity and these aspects do not allow direct comparison with inactivation rate. To determine the hydroxylation more accurately and correlate the data with inactivation at the amino acid level, the aliquots of synchrotron-irradiated sCJD MM1, MM2 and VV2 prions were, after formic acid denaturation, digested with pepsin and analyzed by MS/MS spectrometer coupled with UPLC. The optimized pepsin digestion generated overlapping peptide coverage of the prion core (S2 Table), and the modification rate was calculated from integrated peak areas of modified and unmodified peptides.

The initial analysis of non-irradiated MS data revealed that some modifications of side chains, notably methionine, occurred before irradiation. The degree of hydroxylation follows the susceptibility of individual amino acids expected from the peptide experiments: Cys > Met > Trp > Tyr > Phe > Cystine > His > Leu ~ Ile > Arg ~ Lys > Ser ~ Thr > Pro ~ Gln ~ Glu > Asp ~ Asn > Ala > Gly [61, 66]. High relative reactivity of methionine and high content in human prion core (10 out of 137 amino acids is methionine), this amino acid is a particularly useful indicator of solvent accessibility [35, 61, 66, 67] (Fig 4A and S2 and S3 Tables). The sCJD VV2 prions have the highest proportion of hydroxylated residues followed by MM2 and MM1, even though the purification was performed at low temperatures and buffers that do not generate •OHs. Cumulatively, the modification of amino acids 129–136, 154, and 162–167 residues in MM1, MM2, and VV2 prions indicate that these domains were exposed to •OHs during the accumulation in human brains in vivo. Whether this effect is due to the extended half-life of different prions in the brain we observed in rodent models [68], disease-induced oxidative stress, or combination of both will require time course study in transgenic mice.

The residue specific modification rates of MM1, MM2 and VV2 calculated by plotting exposure time vs fraction of unmodified peptides using the first order rate equation were determined for 23 residues (S3 Table) spanning the prion core sequence downstream from
residue Y128 (Figs 4B and S1). Unfortunately, ragged cleavage sites generated at the N-terminus by Proteinase K during purification [69] did not yield reproducible peptide coverage upstream from Y128 residue (Figs 1 and 2). The sCJD MM1, MM2, and VV2 prion strains showed significant differences in oxidation rate profiles indicative of variable exposure to the solvent (Figs 4B and S1). As shown previously with dCDI, the VV2 prions demonstrated the highest rates of hydroxylation through the whole core, followed by MM2, and MM1 prions, indicating that the VV2 prions have the least protected amino acid side chains in a unique
structural organization. The hydroxylation expressed as rates (S1 Fig and S3 Table) and half-life (Fig 4B) varied broadly within 4 orders of magnitude and highly protected residues clustered within three distinct domains: amino acids 136–162, 167–175, and 218–225. In contrast to MM2 and VV prions, the Y163, P165, and Y169 residues were completely protected in MM1 prions and thus the half-life couldn’t be calculated (Figs 4B and S1). There is no difference in hydroxylation rates of residues M134, Y162, M206, M213 and Y218 in MM1, MM2 and VV2 prions, which suggest that these residues are forming a structural motif common to all three human prion strains (Fig 4B). The rapid rate of hydroxylation in domains 129–134, M166, and 206–213 correlated with rapid inactivation of MM1 and MM2 prions in seeding RT QuIC assays (Fig 3D). Notably, those are the residues that underwent hydroxylation before synchrotron irradiation, and implicate differential modification rates during the accumulation in the brains (Fig 4A).

Next, we calculated the protection factor by dividing the modification rate of residue in recombinant human prion protein (recPrP) containing either 129M or 129V (S1 Fig and S4 Table) by modification rate of same residue in PrP\textsuperscript{Sc} (MM1, MM2 and VV2) and model the residue distribution using the solution NMR structure of human recPrP (1QM0) deposited in PDB [70]. The model is indicative of a major alteration in solvent accessibility of surface residues during conversion of monomeric prion protein where the helix structures of the monomer become buried in presumably beta sheet structured prion particles (Fig 5A, 5B, 5C and 5D). With the exception of R136 in VV2 prions, all other monitored residues underwent a major strain-specific structural rearrangement in the conformational transition from α-helical monomer to beta-sheet structured prion particles, resulting in a high protection from solvent. The amino acid side chains in a 166–175 domain of human prions are relatively exposed to the solvent, and the residue F175 shows a major difference in the accessibility in MM1, MM2, and VV2 strains of human prions. Notably, the 165–177 domain is forming a beta2-alfa2 loop in the cellular prion protein (PrPC) and dramatically influences the interspecies prion transmission of sheep scrapie, BSE, mouse-adapted scrapie, deer chronic wasting disease, and hamster-adapted scrapie prions [71]. This loop may exist in two alternative conformations (3\textsubscript{10}-helix turn or type I beta-turn) and for example replacement of Y169G result in a PrPC containing only the type—I beta-turn loop—structure [71, 72] and different interspecies transmission profile of prions. Cumulatively, these and our data suggest that this particular domain plays a major role in the conformational transition from cellular prion protein to prions, and thus determine the infectivity and interspecies transmissibility of human prions as well.

Discussion

The misfolded human prion protein, PrP\textsuperscript{Sc}, is the essential, and possibly sole component of infectious human prions [24]. However, a high-resolution structure of human prions is lacking, and the key molecular mechanisms that determine initiation and propagation under physiological conditions—human prion infectivity—remain obscure [22, 24, 73]. Our investigations of the structure and replication potency of major human prions with synchrotron \textbullet OH footprinting monitored with MS and dCDI in this report allowed us to establish the fundamental structural attributes of infectivity of the major human brain-derived prions. Our present study demonstrates, for the first time, that replication as well as inactivation of different strains of infectious human prions is primarily driven by the distinct structural organization of their external domains. Furthermore, the major differences in infectivity, as well as inactivation susceptibility, appear to be controlled by seemingly subtle differences in the conformation, especially in the N- terminal and C-terminal domain, which in PrP is involved in posttranslational modifications [9–11, 23].
Human prion diseases are conceivably the most heterogenous neurodegenerative disorders and a growing body of research indicates that they are caused by distinct strains of human prions [9–11, 22]. However, the structural studies of human prions have lagged behind the recent progress in rodent laboratory prions, in part because of their complex molecular characteristics and prohibitive biosafety requirements for laboratory experiments and bioassays, due to the human-to-human transmissibility of disease which is invariably fatal and has no treatment. The early discovery of distinct polymorphic PK cleavage sites in human brain-derived PrPSc has been used for the clinicopathological diagnostic classifications of sCJD cases; and in concert with the codon 129 PRNP haplotype, the different protease-resistant fragments of PrPSc protein (rPrPSc) types broadly correlate with distinct disease phenotypes (Fig 1) [74–79]. The majority of sCJD patients are homozygous for methionine in codon 129 of the PRNP gene, accumulate Type 1 rPrPSc, with disease duration of approximately 4 months (Fig 1) and fine punctate (synaptic) deposits of PrPSc [36, 75]. In contrast, patients with the second most frequent phenotype are homozygous for valine in codon 129 of the PRNP gene, accumulate Type 2 PrPSc and manifest a different disease course, with early ataxia, predominant extrapyramidal symptoms, relatively late-onset dementia in the extended course of the disease, and large...
plaque-like deposits of PrPSc [11, 75]. The sCJD VV2 subtype has typically the longer duration, with major deposits of plaque forming PrPSc in the cerebellum [9–11].

The molecular mechanisms that are being debated in support of human prion strain phenomenon are (i) packing polymorphism, in which the same segment of protein guides alternative packing of β-sheets [80, 81]; (ii) segmental polymorphism, in which a different segment of protein encodes different β-sheet formation [82]; and (iii) structural and kinetic effect of different auxiliary ligands [24]. However, the high resolution structure of human prions is lacking and our recent hydrogen/deuterium amide exchange data on sCJD MM1, MM2, and synthetic human prions provide evidence that human prions differ significantly from noninfectious prion protein amyloid and rodent prions [22–24]. Furthermore, our data indicate that, in contrast to previous observations on yeast and some laboratory rodent prion strains, the replication rate of sCJD prions is primarily determined not by conformational stability (or fragmentation susceptibility), but by structural features that control the growth rate of prion protein aggregates [22, 24].

The differential, but generally very slow exchange rate of amide bonds in peptides covering 128–162, and 167–214 domains is indicative that these two domains are forming a β-sheet structure in human prions; this supports the in-register parallel model observed with solid state NMR in a recombinant C-terminally truncated fragment of mouse PrP23-144 [23, 83]. The early radiobiological investigations on the resistance of prions to inactivation by ionizing radiation, played a critical role in establishing the small target size [84, 85], and the independence of infectivity on nucleic acid [86], and thus these findings provided a foundation for the formulation of the prion concept as a self-replicating protein [1]. Building on these approaches, we identified three domains—Y128-M134, Y163-M166, and M206-M213—with a high rate of •OH modification during synchrotron radiolysis, indicating significant solvent exposure that correlated with inactivation of prion seeding activity. Prior MS studies of human brain-derived prion fragments generated with Proteinase K identified additional truncated C-terminal fragments (CTFs): 13kDa CTF fragment with cleavage site in residues 154–156, and 12kDa fragment starting at residues 162–167 of human brain-derived PrPSc [22, 87]. These and our data on solvent accessibility suggest that these residues are forming in human prions a solvent and enzyme exposed loop. Additional cleavage sites in residue 134 and 169 found in laboratory rodent prions correspond to solvent exposed domains in human prions, but the rest does not and indicate significant structural differences between human and rodent prions we observed previously with HX MS [22, 88].

All three solvent-exposed human prion domains contain, or are neighbors of, P137, P158, and P165 residues suggesting that they might be involved in forming a loop or turn into a beta sheet structure. Additionally, while comparing solvent accessibility of proline residue between MM1, MM2 and VV2, we found a significant difference in microenvironment around P137 and P165. Such differences in proline residue environment may have a pronounced effect on the tertiary as well as quaternary structure; this might be one of the driving factors that contribute to the formation of prion strains with distinctly different affinity for a substrate PrPSc, and thus different replications rates and toxicity. These structural and inactivation data may open new potential therapeutic strategies for human prion diseases that would target the common solvent-exposed elements of human prions in an early interphase of PrPSc/PrPC interaction.

Supporting information

S1 Fig. Hydroxyl radical modification rate of residues in (a) α-helical monomers of recHuPrP (129M) and rPrP(129V), and (b) sCJD MM1, MM2, and VV2 prions. (TIIF)
S1 Table. End point titration of human prion seeding activity after synchrotron irradiation with RT QuIC. Samples were diluted five-fold and the seeding activity of each sample was monitored in four wells for 60 hrs.

S2 Table. Fragments of MM1, MM2 and VV2 sCJD prions and their sequences showing variable degree of modification rate. Residues colored with green, blue, red and black represents modification rate as >0.0375, 0.0375–0.0075, 0.0075–0.00015 and <0.00015 respectively.

S3 Table. Hydroxyl radical modification rates of MM1, MM2 and VV2 sCJD prions. Note codon 129 polymorphism in 128–133 peptide.

S4 Table. Hydroxyl radical modification rate of residues in monomeric a-helical recHuPrPC(129M) and rPrPC(129V).

Acknowledgments
The authors are grateful to the patients’ families for donating brain tissue and we thank all the referring physicians and all members of the National Prion Disease Pathology Surveillance Center (NPDPSC), Cleveland, Ohio, for technical assistance and review of clinical data.

Author Contributions
Conceptualization: Mohammad Khursheed Siddiqi, Chae Kim, Tracy Haldiman, Miroslava Kacirova, Mark R. Chance, Janna Kiselar, Jiri G. Safar.

Data curation: Mohammad Khursheed Siddiqi, Chae Kim, Tracy Haldiman, Miroslava Kacirova, Benlian Wang, Jen Bohon, Mark R. Chance, Janna Kiselar, Jiri G. Safar.

Formal analysis: Mohammad Khursheed Siddiqi, Chae Kim, Tracy Haldiman, Jen Bohon, Mark R. Chance, Janna Kiselar, Jiri G. Safar.

Investigation: Jiri G. Safar.

Methodology: Miroslava Kacirova, Benlian Wang, Jen Bohon, Janna Kiselar, Jiri G. Safar.

Supervision: Jiri G. Safar.

Writing – original draft: Mohammad Khursheed Siddiqi, Janna Kiselar, Jiri G. Safar.

Writing – review & editing: Mark R. Chance, Janna Kiselar, Jiri G. Safar.

References
1. Prusiner SB (1982) Novel proteinaceous infectious particles cause scrapie. Science 216: 136–144. https://doi.org/10.1126/science.6801762 PMID: 6801762
2. Prusiner SB (1998) Prions. Proc Natl Acad Sci USA 95: 13363–13383. https://doi.org/10.1073/pnas.95.23.13363 PMID: 9811807
3. Prusiner SB, editor (2004) Prion Biology and Diseases. 2nd ed. Cold Spring Harbor: Cold Spring Harbor Laboratory Press. 1050 p.
4. Caughey B, Baron GS, Chesebro B, Jeffrey M (2009) Getting a grip on prions: oligomers, amyloids, and pathological membrane interactions. Annu Rev Biochem 78: 177–204. https://doi.org/10.1146/annurev.biochem.78.092907.145410 PMID: 19231987
5. Cobb NJ, Surewicz WK (2009) Prion diseases and their biochemical mechanisms. Biochemistry 48: 2574–2585. https://doi.org/10.1021/bi900108v PMID: 19239250
6. Collinge J, Clarke AR (2007) A general model of prion strains and their pathogenicity. Science 318: 930–936. https://doi.org/10.1126/science.1138718 PMID: 17991853

7. Morales R, Abid K, Soto C (2007) The prion strain phenomenon: molecular basis and unprecedented features. Biochim Biophys Acta 1772: 681–691. https://doi.org/10.1016/j.bbadis.2006.12.006 PMID: 17254754

8. Prusiner SB, Scott MR, DeArmond SJ, Cohen FE (1998) Prion protein biology. Cell 93: 337–348. https://doi.org/10.1016/S0092-8674(00)81163-0 PMID: 9590169

9. Safar JG (2012) Molecular pathogenesis of sporadic prion diseases in man. Prion 6: 108–115. https://doi.org/10.4161/pril.18666 PMID: 22421210

10. Safar JG (2012) Molecular Mechanisms Encoding Quantitative and Qualitative Traits of Prion Strains. In: Zou WaG P., editor. Prions and Diseases. New York: Springer Verlag.

11. Puoti G, Bizzzi A, Forloni G, Safar JG, Tagliavini F, et al. (2012) Sporadic human prion diseases: molecular insights and diagnosis. Lancet Neurol 11: 618–628. https://doi.org/10.1016/S1474-4422(12)70063-7 PMID: 22710755

12. Haldiman T, Kim C, Cohen Y, Chen W, Blevins J, et al. (2013) Co-existence of distinct prion types enables conformational evolution of human PrPSc by competitive selection. J Biol Chem 288: 29846–29861. https://doi.org/10.1074/jbc.M113.500108 PMID: 23974118

13. Deleault NR, Harris BT, Rees JR, Supattapon S (2007) Formation of native prions from minimal components in vitro. Proc Natl Acad Sci USA 104: 9741–9746. https://doi.org/10.1073/pnas.0702662104 PMID: 17535913

14. Makarava N, Kovacs GG, Bocharova O, Savtchenko R, Alexeeva I, et al. (2010) Recombinant prion protein induces a new transmissible prion disease in wild-type animals. Acta Neuropathol 119: 177–187. https://doi.org/10.1007/s00401-009-0633-x PMID: 20052481

15. Zhang Z, Zhang Y, Wang F, Wang X, Xu Y, et al. (2013) De novo generation of infectious prions with bacterially expressed recombinant prion protein. FASEB J 27: 4768–4775. https://doi.org/10.1096/fj.13-233965 PMID: 23970796

16. Legname G, Nguyen H-OB, Baskakov IV, Cohen FE, DeArmond SJ, et al. (2005) Strain-specific characteristics of mouse synthetic prions. Proc Natl Acad Sci USA 102: 2168–2173. https://doi.org/10.1073/pnas.0409079102 PMID: 15671162

17. Kim JL, Cali I, Surewicz K, Kong Q, Raymond GJ, et al. (2010) Mammalian prions generated from bacterial expression protein in the absence of any mammalian cofactors. J Biol Chem 285: 14083–14087. https://doi.org/10.1074/jbc.C110.113464 PMID: 20304915

18. Theint T, Nadaud PS, Surewicz K, Surewicz WK, Jaroniec CP (2017) 13C and 15N chemical shift assignments of mammalian Y145Stop prion protein amyloid fibrils. Biomol NMR Assign 11: 75–80. https://doi.org/10.1007/s12104-016-9723-6 PMID: 28004358

19. Choi JK, Cali I, Surewicz K, Kong Q, Gambetti P, et al. (2016) Amyloid fibrils from the N-terminal prion protein fragment are infectious. Proc Natl Acad Sci U S A 113: 13851–13856. https://doi.org/10.1073/pnas.1610716113 PMID: 27849581

20. Noble GP, Wang DW, Walsh DJ, Barone JR, Miller MB, et al. (2015) A Structural and Functional Comparison Between Infectious and Non-Infectious Autocatalytic Recombinant PrP Conformers. PLoS Pathog 11: e1005017. https://doi.org/10.1371/journal.ppat.1005017 PMID: 26125623

21. Klingeborn M, Race B, Meade-White KD, Chesebro B (2011) Lower specific infectivity of protease-resistant prion protein generated in cell-free reactions. Proc Natl Acad Sci U S A 108: E1244–1253. https://doi.org/10.1073/pnas.1111255108 PMID: 22065744

22. Safar JG, Xiao X, Kabir ME, Chen S, Kim C, et al. (2015) Structural determinants of phenotypic diversity and replication rate of human prions. PLoS Pathog 11: e1004832. https://doi.org/10.1371/journal.ppat.1004832 PMID: 25875953

23. Li Q, Wang F, Xiao X, Kim C, Bohon J, et al. (2018) Structural attributes of mammalian prion infectivity: Insights from studies with synthetic prions. J Biol Chem 293: 18494–18503. https://doi.org/10.1074/jbc.RA118.005622 PMID: 30275016

24. Kim C, Xiao X, Chen S, Haldiman T, Smirnovas V, et al. (2018) Artificial strain of human prions created in vitro. Nat Commun 9. https://doi.org/10.1038/s41467-018-04584-z PMID: 29867164

25. Asher DM, Belay E, Bigio E, Brandner S, Brubaker SA, et al. (2020) Risk of Transmissibility From Neurodegenerative Disease-Associated Proteins: Experimental Knowns and Unknowns. J Neuropathol Exp Neurol 79: 1141–1146. https://doi.org/10.1093/jnen/lnaa109 PMID: 33000167

26. Kang SG, Eskandari-Sedighi G, Hromadkova L, Safar JG, Westaway D (2020) Cellular Biology of Tau Diversity and Pathogenic Conformers. Front Neurol 11: 590199. https://doi.org/10.3389/fneur.2020.590199 PMID: 33304310
27. Daude N, Kim C, Kang SG, Eskandari-Sedighi G, Haldimann T, et al. (2020) Diverse, evolving conformer populations drive distinct phenotypes in frontotemporal lobar degeneration caused by the same MAPT-P301L mutation. Acta Neuropathol 139: 1045–1070. https://doi.org/10.1007/s00401-020-02148-4 PMID: 32219515

28. Cali I, Castellani R, Alshekhlee A, Cohen Y, Blevins J, et al. (2009) Co-existence of scrapie prion protein types 1 and 2 in sporadic Creutzfeldt-Jakob disease: its effect on the phenotype and prion-type characteristics. Brain 132: 2643–2658. https://doi.org/10.1093/brain/awp196 PMID: 19734922

29. Kim C, Haldimann T, Surewicz K, Cohen Y, Chen W, et al. (2012) Small Protease Sensitive Oligomers of PrP(Sc) in Distinct Human Prions Determine Conversion Rate of PrP(C). PLoS Pathog 8: e1002385. https://doi.org/10.1371/journal.ppat.1002385 PMID: 22876179

30. Kim C, Haldimann T, Cohen Y, Chen W, Blevins J, et al. (2011) Protease-Sensitive Conformers in Broad Spectrum of Distinct PrP Structures in Sporadic Creutzfeldt-Jakob Disease Are Indicator of Progression Rate. PLoS Pathog 7: e1002242. https://doi.org/10.1371/journal.ppat.1002242 PMID: 21931554

31. Safar J, Wang W, Padgett MP, Ceroni M, Piccardo P, et al. (1990) Molecular mass, biochemical composition, and physicochemical behavior of the infectious form of the scrapie precursor protein monomer. Proc Natl Acad Sci USA 87: 6373–6377. https://doi.org/10.1073/pnas.87.16.6373 PMID: 1974720

32. Safar J, Roller PP, Gajdusek DC, Gibbs CJ Jr. (1993) Conformational transitions, dissociation, and unfolding of scrapie amyloid (prion) protein. J Biol Chem 268: 20276–20284. PMID: 8104185

33. Safar J, Roller PP, Gajdusek DC, Gibbs CJ Jr. (1993) Thermal stability and conformational transitions of scrapie amyloid (prion) protein correlate with infectivity. Protein Sci 2: 2206–2216. https://doi.org/10.1002/pro.556021220 PMID: 7905316

34. Gupta S, Sullivan M, Tooney J, Kiselar J, Chance MR (2005) Secondary reactions and strategies to improve quantitative protein footprinting. Anal Chem 77: 3029–3037. https://doi.org/10.1021/ac048282z PMID: 15889890

35. Xu G, Kiselar J, He Q, Chance MR (2005) Secondary reactions and strategies to improve quantitative protein footprinting. Anal Chem 77: 3029–3037. https://doi.org/10.1021/ac048282z PMID: 15889890

36. Safar JG, Geschwind MD, Deering C, Didorenko S, Sattavat M, et al. (2005) Diagnosis of human prion disease. Proc Natl Acad Sci USA 102: 3501–3506. https://doi.org/10.1073/pnas.0409651102 PMID: 15741275

37. Zanusso G, Liu D, Ferrari S, Hegyi I, Yin X, et al. (1998) Prion protein expression in different species: Analysis with a panel of new mAbs. Proc Natl Acad Sci USA 95: 8812–8816. https://doi.org/10.1073/pnas.95.15.8812 PMID: 9671761

38. Safar J, Prusiner SB (1998) Molecular studies of prion diseases. Prog Brain Res 12: 27–33. PMID: 10.1016/s0079-6123 (98)64030-3 PMID: 9932423

39. Safar J, Wille H, Itri V, Groth D, Serban H, et al. (1998) Eight prion strains have PrP39. Proc Natl Acad Sci USA 95: 8812–8816. https://doi.org/10.1073/pnas.95.15.8812 PMID: 9671761

40. Prusiner SB, Tremblay P, Safar J, Torchia M, DeArmond SJ (1999) Diagnosis and pathogenesis of prion diseases. Biomed Prog 12: 27–33.

41. Foutz A, Appleby BS, Hamlin C, Liu X, Yang S, et al. (2017) Diagnostic and prognostic value of human prion detection in cerebrospinal fluid. Ann Neurol 81: 79–92. https://doi.org/10.1002/ana.24833 PMID: 27893164

42. Kärber G (1931) Beitrag zur kollektiven behandlung pharmakologisheher reiherversuche. Arch Exp Path Pharmacol 162: 480–484.

43. Safar JG, Scott M, Monaghan J, Deering C, Didorenko S, et al. (2002) Measuring prions causing bovine spongiform encephalopathy or chronic wasting disease by immunosassays and transgenic mice. Nat Biotechnol 20: 1147–1150. https://doi.org/10.1038/nbt748 PMID: 12389035

44. Fotsch A, Appleby BS, Hamlin C, Liu X, Yang S, et al. (2017) Diagnostic and prognostic value of human prion detection in cerebrospinal fluid. Ann Neurol 81: 79–92. https://doi.org/10.1002/ana.24833 PMID: 27893164

45. Kärber G (1931) Beitrag zur kollektiven behandlung pharmakologisheher reiherversuche. Arch Exp Path Pharmacol 162: 480–484.

46. Wilham JM, Orru CD, Bessen RA, Atarashi R, Sano K, et al. (2010) Rapid end-point quantitation of prion seeding activity with sensitivity comparable to bioassays. PLoS Pathog 6: e1001217. https://doi.org/10.1371/journal.ppat.1001217 PMID: 21152012

47. Kascak RJ, Rubenstein R, Merz PA, Tonna-Demasi M, Fersko R, et al. (1987) Mouse polyclonal and monoclonal antibody to scrapie-associated fibril proteins. J Virol 61: 3688–3693. https://doi.org/10.1128/JVI.61.12.3688-3693.1987 PMID: 2446004
48. Bellon A, Seyfert-Brandt W, Lang W, Baron H, Groner A, et al. (2003) Improved conformation-dependant immunoassay: suitability for human prion detection with enhanced sensitivity. J Gen Virol 84: 1921–1925. https://doi.org/10.1099/vir.0.18996-0 PMID: 12810888

49. Kisela JG, Maleknia SD, Sullivan M, Downard KM, Chance MR (2002) Hydroxyl radical probe of protein surfaces using synchrotron X-ray radiolysis and mass spectrometry. Int J Radiat Biol 78: 101–114. https://doi.org/10.1080/09553000110094805 PMID: 11779360

50. Takamoto K, Chance MR (2006) Radiolytic protein footprinting with mass spectrometry to probe the structure of macromolecular complexes. Annu Rev Biophys Biomol Struct 35: 251–276. https://doi.org/10.1146/annurev.biophys.35.040405.102050 PMID: 16689636

51. Miyagi M, Nakazawa T (2008) Determination of pKa values of individual histidine residues in proteins using mass spectrometry. Anal Chem 80: 6481–6487. https://doi.org/10.1021/ac8009643 PMID: 18665614

52. Miyagi M, Wang Q, Ahmad MF, Gokulrangan G, Tomechk o SE, et al. (2011) Histidine hydrogen-deuterium exchange mass spectrometry for probing the microenvironment of histidine residues in dihydrofolate reductase. PLoS One 6: e17055. https://doi.org/10.1371/journal.pone.0017055 PMID: 21359214

53. Xu G, Chance MR (2005) Radiolytic modification and reactivity of amino acid residues serving as structural probes for protein footprinting. Analytical chemistry 77: 4549–4555. https://doi.org/10.1021/ac050299+ PMID: 16013872

54. Xu G, Chance MR (2007) Hydroxyl radical-mediated modification of proteins as probes for structural proteomics. Chemical reviews 107: 3514–3543. https://doi.org/10.1021/cr0682047 PMID: 17683160

55. van den Berg RA, Hoefsloot HC, Westerhuis JA, Smilde AK, van der Werf MJ (2006) Centering, scaling, and transformations: improving the biological information content of metabolomics data. BMC genomics 7: 142. https://doi.org/10.1186/1471-2164-7-142 PMID: 16762068

56. Safar JG, Giles K, Lessard P, Letessier F, Patel S, et al. (2011) Conserved properties of human and bovine prion strains on transmission to guinea pigs. Lab Invest 91: 517–529. https://doi.org/10.1038/ls0401-012-1002-8 PMID: 22744790

57. Bellon A, Seyfert-Brandt W, Lang W, Baron H, Groner A, et al. (2003) Improved conformation-dependant immunoassay: suitability for human prion detection with enhanced sensitivity. J Gen Virol 84: 1921–1925. https://doi.org/10.1099/vir.0.18996-0 PMID: 12810888

58. Maleknia SD, Kisela JG, Downard KM (2002) Hydroxyl radical probe of the surface of lysozyme by synchrotron radiolysis and mass spectrometry. Int J Radiat Biol 78: 101–114. https://doi.org/10.1080/09553000110094805 PMID: 11779360

59. Takamoto K, Chance MR (2006) Radiolytic protein footprinting with mass spectrometry to probe the structure of macromolecular complexes. Annu Rev Biophys Biomol Struct 35: 251–276. https://doi.org/10.1146/annurev.biophys.35.040405.102050 PMID: 16689636

60. Maleknia SD, Downard KM (2001) Radical approaches to probe protein structure, folding, and interactions by mass spectrometry. Mass Spectrom Rev 20: 388–401. https://doi.org/10.1002/mas.10013 PMID: 11997945

61. Kaur P, Kisela J, Yang S, Chance MR (2015) Quantitative protein topography analysis and high-resolution structure prediction using hydroxyl radical labeling and tandem-ion mass spectrometry (MS). Mol Cell Proteomics 14: 1159–1168. https://doi.org/10.1074/mcp.O114.044362 PMID: 25687570

62. Maleknia SD, Kiselar JG, Sullivan M, Downard KM, Chance MR (2002) Hydroxyl radical probe of protein surfaces using synchrotron X-ray radiolysis and mass spectrometry. Int J Radiat Biol 78: 101–114. https://doi.org/10.1080/09553000110094805 PMID: 11779360

63. Atarashi R, Satoh K, Sano K, Fuse T, Yamaguchi N, et al. (2011) Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion. Nat Med 17: 175–178. https://doi.org/10.1038/nm.2294 PMID: 21278748

64. Orru CD, Yuan J, Appleby BS, Li B, Li Y, et al. (2017) Prion seeding activity and infectivity in skin samples from patients with sporadic Creutzfeldt-Jakob disease. Sci Transl Med 9. https://doi.org/10.1126/scitranslmed.aam7785 PMID: 29167394

65. Atarashi R, Satoh K, Sano K, Fuse T, Yamaguchi N, et al. (2011) Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion. Nat Med 17: 175–178. https://doi.org/10.1038/nm.2294 PMID: 21278748

66. Maleknia SD, Downard K (2001) Radical approaches to probe protein structure, folding, and interactions by mass spectrometry. Mass Spectrom Rev 20: 388–401. https://doi.org/10.1002/mas.10013 PMID: 11997945

67. Kaur P, Kisela J, Yang S, Chance MR (2015) Quantitative protein topography analysis and high-resolution structure prediction using hydroxyl radical labeling and tandem-ion mass spectrometry (MS). Mol Cell Proteomics 14: 1159–1168. https://doi.org/10.1074/mcp.O114.044362 PMID: 25687570
68. Safar JG, DeArmond SJ, Kociuba K, Deering C, Didorenko S, et al. (2005) Prion clearance in bigenic mice. J Gen Virol 86: 2913–2923. https://doi.org/10.1099/vir.0.80947-0 PMID: 16186247

69. Parchi P, Zou W, Wang W, Brown P, Capellari S, et al. (2000) Genetic influence on the structural variations of the abnormal prion protein. Proc Natl Acad Sci USA 97: 10168–10172. https://doi.org/10.1073/pnas.97.18.10168 PMID: 10963679

70. Zahn R, Liu A, Lührs T, Riek R, von Schroetter C, et al. (2000) NMR solution structure of the human prion protein. Proc Natl Acad Sci USA 97: 145–150. https://doi.org/10.1073/pnas.97.1.145 PMID: 10618385

71. Kurt TD, Jiang L, Fernandez-Borges N, Bett C, Liu J, et al. (2015) Human prion protein sequence elements impede cross-species chronic wasting disease transmission. J Clin Invest 125: 1485–1496. https://doi.org/10.1172/JCI79408 PMID: 25705888

72. Damberger FF, Christen B, Pérez DR, Hornemann S, Wüthrich K (2011) Cellular prion protein conformation and function. Proc Natl Acad Sci U S A 108: 17308–17313. https://doi.org/10.1073/pnas.1106325108 PMID: 21987789

73. Groveman BR, Raymond GJ, Campbell KJ, Race B, Raymond LD, et al. (2017) Role of the central lysine cluster and scrapie templating in the transmissibility of synthetic prion protein aggregates. PLoS Pathog 13: e1006623. https://doi.org/10.1371/journal.ppat.1006623 PMID: 28910420

74. Hill AF, Desbruslais M, Joiner S, Sidle KCL, Gowland I, et al. (1997) The same prion strain causes vCJD and BSE. Nature 389: 448–450. https://doi.org/10.1038/389448a0 PMID: 9332323

75. Gambetti P, Kong Q, Zou W, Parchi P, Chen SG (2003) Sporadic and familial CJD: classification and characterisation. Br Med Bull 66: 213–239. https://doi.org/10.1093/bmb/66.1.213 PMID: 14522861

76. Wadsworth JD, Hill AF, Beck JA, Collinge J (2003) Molecular and clinical classification of human prion disease. Br Med Bull 66: 241–254. https://doi.org/10.1093/bmb/66.1.241 PMID: 14522862

77. Monari L, Chen SG, Brown P, Parchi P, Petersen RB, et al. (1994) Fatal familial insomnia and familial Creutzfeldt-Jakob disease: different prion proteins determined by a DNA polymorphism. Proc Natl Acad Sci USA 91: 2839–2842. https://doi.org/10.1073/pnas.91.7.2839 PMID: 7908444

78. Telling GC, Parchi P, DeArmond SJ, Cortelli P, Montagna P, et al. (1996) Evidence for the conformation of the pathologic isoform of the prion protein encephering and propagating prion diversity. Science 274: 2079–2082. https://doi.org/10.1126/science.274.5295.2079 PMID: 8953038

79. Parchi P, Castellani R, Capellari S, Ghetti B, Young K, et al. (1996) Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol 39: 767–778. https://doi.org/10.1002/ana.410390613 PMID: 8651649

80. Theint T, Nadaud PS, Aucoupin D, Helmus JJ, Pondaven SP, et al. (2017) Species-dependent structural polymorphism of Y145Stop prion protein amyloid revealed by solid-state NMR spectroscopy. Nat Commun 8: 753. https://doi.org/10.1038/s41467-017-00794-z PMID: 28963458

81. Vazquez-Fernandez E, Vos MR, Afanasyev P, Cebey L, Sevilla no AM, et al. (2016) The Structural Architecture of an Infectious Mammalian Prion Using Electron Cryomicroscopy. PLoS Pathog 12: e1005835. https://doi.org/10.1371/journal.ppat.1005835 PMID: 27606840

82. Groveman BR, Dolan MA, Taubner LM, Kraus A, Wickner RB, et al. (2014) Parallel in-register intermolecular beta-sheet architectures for prion-seeded prion protein (PrP) amyloids. J Biol Chem 289: 24129–24142. https://doi.org/10.1074/jbc.M114.578344 PMID: 25028516

83. Aucoupin D, Xia Y, Theint T, Nadaud PS, Surewicz K, et al. (2019) Protein-solvent interfaces in human Y145Stop prion protein amyloid fibrils probed by paramagnetic solid-state NMR spectroscopy. J Struct Biol 206: 36–42. https://doi.org/10.1016/j.jsb.2018.04.002 PMID: 29679649

84. Alper T, Haig DA, Clarke MC (1978) The scrapie agent: evidence against its dependence for replication on intrinsic nucleic acid. J Gen Virol 41: 503–516. https://doi.org/10.1099/0022-1317-41-3-503 PMID: 106090

85. Alper T, Haig DA, Clarke MC (1966) The exceptionally small size of the scrapie agent. Biochem Biophys Res Commun 22: 278–284. https://doi.org/10.1016/0006-291X(66)90478-5 PMID: 4957205

86. Bellinger-Kawahara CG, Kempner E, Groth DF, Gabizon R, Prusiner SB (1988) Scaprine prion liposomes and rods exhibit target sizes of 55,000 Da. Virology 164: 537–541. https://doi.org/10.1016/0042-6822(88)90569-7 PMID: 3130718

87. Zou WQ, Capellari S, Parchi P, Sy MS, Gambetti P, et al. (2003) Identification of novel proteinase K-resistant C-terminal fragments of PrP in Creutzfeldt-Jakob disease. J Biol Chem 278: 40429–40436. https://doi.org/10.1074/jbc.M308550200 PMID: 12917418

88. Sajnani G, Pastrana MA, Dynin I, Onisko B, Requena JR (2008) Scaprine prion protein structural constraints obtained by limited proteolysis and mass spectrometry. J Mol Biol 382: 88–98. https://doi.org/10.1016/j.jmb.2008.06.070 PMID: 18621059
89. Parchi P, Capellari S, Chen SG, Petersen RB, Gambetti P, et al. (1997) Typing prion isoforms. Nature 386: 232–233. https://doi.org/10.1038/386232a0 PMID: 9069279

90. Langeveld JP, Jacobs JG, Erkens JH, Bossers A, van Zijderve ld FG, et al. (2006) Rapid and discriminatory diagnosis of scrapie and BSE in retro-pharyngeal lymph nodes of sheep. BMC Vet Res 2: 19. https://doi.org/10.1186/1746-6148-2-19 PMID: 16764717

91. Chen SG, Teplow DB, Parchi P, Teller JK, Gambetti P, et al. (1995) Truncated forms of the human prion protein in normal brain and in prion diseases. J Biol Chem 270: 19173–19180. https://doi.org/10.1074/jbc.270.32.19173 PMID: 7642585